Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
MDGL
MDGL
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
MDGL News
Undervalued Investment Opportunities: Axsome and Madrigal
4h ago
Fool
Axsome and Madrigal's Market Potential
4h ago
NASDAQ.COM
Madrigal (MDGL) Q4 2025 Earnings Call Transcript
Feb 23 2026
NASDAQ.COM
Baker Bros. Advisors Increases Stake in Kymera Therapeutics
Feb 23 2026
Yahoo Finance
U.S. Markets Fell on Thursday; Klarna Group Reported Largest Loss
Feb 19 2026
Barron's
Madrigal Pharmaceuticals Q4 2025 Earnings Call Highlights
Feb 19 2026
seekingalpha
Madrigal Pharmaceuticals Reports Mixed Q4 2025 Earnings
Feb 19 2026
seekingalpha
Madrigal Pharmaceuticals Q4 2025 Earnings Analysis
Feb 19 2026
seekingalpha
Madrigal Pharmaceuticals Q4 Earnings Preview
Feb 18 2026
seekingalpha
Madrigal Pharmaceuticals Shares Enter Oversold Territory
Feb 13 2026
NASDAQ.COM
Ribo Life Science and Madrigal Sign siRNA Licensing Agreement
Feb 12 2026
PRnewswire
Ribo and Madrigal Sign Exclusive Global License Agreement
Feb 12 2026
PRnewswire
Ribo and Madrigal Announce Exclusive Global License Agreement
Feb 11 2026
PRnewswire
Madrigal Pharmaceuticals Enters $4.46B Licensing Deal with Suzhou Ribo
Feb 11 2026
seekingalpha
Ribo Life Science Enters Exclusive Licensing Agreement with Madrigal Pharmaceuticals
Feb 11 2026
PRnewswire
Ribo Life Science Enters Exclusive Licensing Agreement with Madrigal Pharmaceuticals
Feb 11 2026
PRnewswire
Show More News
